Halozyme Therapeutics (HALO) EPS: History & Chart

Halozyme Therapeutics, Inc.(HALO)

Biotechnology · San Diego, CA

$110.30+1.99 (+1.84%)

Delayed quote: Oct 6, 2026, 1:55 PM EDT

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biopharmaceutical company headquartered in San Diego, California, with operations spanning the United States, Switzerland, Ireland, Belgium, Japan, and other international markets. At its core is the proprietary ENHANZE drug delivery platform, which utilizes a patented recombinant human hyaluronidase enzyme (rHuPH20). This innovative technology significantly enhances the subcutaneous (under-the-skin) administration of a diverse range of injectable medicines. This includes complex biologics such as monoclonal antibodies, various other therapeutic molecules, smaller drug compounds, and even fluids. The company's leading product, Hylenex recombinant, is an rHuPH20 formulation specifically designed to facilitate subcutaneous fluid delivery for hydration. It also plays a crucial role in improving the dispersion and absorption of other injected drugs during subcutaneous urography, and aids in the resorption of radiopaque agents. Halozyme also offers several key therapeutics leveraging its platform, including Perjeta, RITUXAN HYCELA, and MabThera SC, which are used to treat non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL). RITUXAN SC is another offering for CLL patients, while HYQVIA addresses various immunodeficiency disorders. Their development pipeline boasts numerous investigational drugs, such as Tecentriq for non-small cell lung cancer, OCREVUS for multiple sclerosis, and DARZALEX, which targets amyloidosis, smoldering myeloma, and multiple myeloma. Other pipeline candidates include nivolumab for solid tumors, ARGX-113 (a human neonatal Fc receptor), ARGX-117 for autoimmune diseases, and BMS-986179, an anti-CD-73 antibody. Halozyme maintains extensive collaborations with prominent pharmaceutical companies like F. Hoffmann-La Roche, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, and Horizon Therapeutics plc. They also partner with research institutions such as the National Institute of Allergy and Infectious Diseases, the Centre for the AIDS Programme of Research in South Africa, and ViiV Healthcare Limited, particularly focusing on both small and large molecule targets for the treatment and prevention of HIV. The company was established in 1998.

San Diego, CA

423 employees

www.halozyme.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Helen I. Torley

View full financials

HALO Earnings Per Share (EPS) Metrics

EARNINGS PER SHARE (EPS)

3.35

EARNINGS PER SHARE (EPS) AVG TTM

3.07

EARNINGS PER SHARE (EPS) AVG 3Y

2.44

EARNINGS PER SHARE (EPS) AVG 5Y

2.26

EARNINGS PER SHARE (EPS) AVG 10Y

1.08

EARNINGS PER SHARE (EPS) AVG 15Y

0.59

EARNINGS PER SHARE (EPS) AVG 20Y

0.19

CURRENT VS TTM AVG

+9.12%

CURRENT VS 3Y AVG

+37.44%

CURRENT VS 5Y AVG

+48.23%

CURRENT VS 10Y AVG

+209.66%

CURRENT VS 15Y AVG

+472.04%

CURRENT VS 20Y AVG

+1677.19%

NAME	MARKET CAP	EARNINGS PER SHARE (EPS)	TTM	3Y	5Y
Halozyme Therapeutics, Inc. (HALO)	$13.08B	3.35	3.07	2.44	2.26
BridgeBio Pharma, Inc. (BBIO)vs ›	$13.11B	-3.58	-3.33	-3.49	-3.66
Tempus AI, Inc. (TEM)vs ›	$12.86B	-1.44	-3.00	-2.43	-2.16
Corcept Therapeutics Incorporated (CORT)vs ›	$12.83B	0.42	1.15	1.07	1.03
Summit Therapeutics Inc. (SMMT)vs ›	$13.60B	N/A	-0.84	-0.70	-0.68
Baxter International Inc. (BAX)vs ›	$12.51B	-2.04	-1.51	-0.65	0.36
Penumbra, Inc. (PEN)vs ›	$12.50B	4.07	2.47	1.81	1.14
BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›	$12.45B	1.34	0.42	-0.09	0.01
ICON Public Limited Company (ICLR)vs ›	$12.43B	4.26	6.26	6.54	5.79
Encompass Health Corporation (EHC)vs ›	$12.35B	6.14	5.08	4.10	3.91

NAME

MARKET CAP

EARNINGS PER SHARE (EPS)

TTM

Halozyme Therapeutics, Inc. (HALO)

$13.08B

3.35

3.07

2.44

2.26

BridgeBio Pharma, Inc. (BBIO)vs ›

$13.11B

-3.58

-3.33

-3.49

-3.66

Tempus AI, Inc. (TEM)vs ›

$12.86B

-1.44

-3.00

-2.43

-2.16

Corcept Therapeutics Incorporated (CORT)vs ›

$12.83B

0.42

1.15

1.07

1.03

Summit Therapeutics Inc. (SMMT)vs ›

$13.60B

N/A

-0.84

-0.70

-0.68

Baxter International Inc. (BAX)vs ›

$12.51B

-2.04

-1.51

-0.65

0.36

Penumbra, Inc. (PEN)vs ›

$12.50B

4.07

2.47

1.81

1.14

BrightSpring Health Services, Inc. Common Stock (BTSG)vs ›

$12.45B

1.34

0.42

-0.09

0.01

ICON Public Limited Company (ICLR)vs ›

$12.43B

4.26

6.26

6.54

5.79

Encompass Health Corporation (EHC)vs ›

$12.35B

6.14

5.08

4.10

3.91

Earnings Per Share (EPS) FAQ

What is the earnings per share (EPS) for Halozyme Therapeutics, Inc. (HALO)?

The earnings per share (EPS) for HALO stock is 3.35.

Is Halozyme Therapeutics, Inc.'s earnings per share (EPS) high or low?

The earnings per share (EPS) of 3.35 is 48% above its 5-year average of 2.26, near the high end of its 5-year range (0.95–3.50).

What is the TTM average earnings per share (EPS) for Halozyme Therapeutics, Inc. (HALO)?

The TTM average earnings per share (EPS) for HALO stock is 3.07.

What is the 3Y average earnings per share (EPS) for Halozyme Therapeutics, Inc. (HALO)?

The 3Y average earnings per share (EPS) for HALO stock is 2.44.

What is the 5Y average earnings per share (EPS) for Halozyme Therapeutics, Inc. (HALO)?

The 5Y average earnings per share (EPS) for HALO stock is 2.26.

What is the 10Y average earnings per share (EPS) for Halozyme Therapeutics, Inc. (HALO)?

The 10Y average earnings per share (EPS) for HALO stock is 1.08.

What is the 15Y average earnings per share (EPS) for Halozyme Therapeutics, Inc. (HALO)?

The 15Y average earnings per share (EPS) for HALO stock is 0.59.

What is the 20Y average earnings per share (EPS) for Halozyme Therapeutics, Inc. (HALO)?

The 20Y average earnings per share (EPS) for HALO stock is 0.19.

DATE	EARNINGS PER SHARE (EPS)
2025-12-31	2.64
2024-12-31	3.50
2023-12-31	2.13
2022-12-31	1.48
2021-12-31	2.86
2020-12-31	0.95
2019-12-31	-0.50
2018-12-31	-0.56
2017-12-31	0.46
2016-12-31	-0.81
2015-12-31	-0.25
2014-12-31	-0.56
2013-12-31	-0.74
2012-12-31	-0.48
2011-12-31	-0.19
2010-12-31	-0.56
2009-12-31	-0.67
2008-12-31	-0.61
2007-12-31	-0.32
2006-12-31	-0.24
2005-12-31	-0.26
2004-12-31	-0.26
2003-12-31	-0.01
2002-12-31	-0.01
2001-12-31	-0.03

DATE

EARNINGS PER SHARE (EPS)

2025-12-31

2.64

2024-12-31

3.50

2023-12-31

2.13

2022-12-31

1.48

2021-12-31

2.86

2020-12-31

0.95

2019-12-31

-0.50

2018-12-31

-0.56

2017-12-31

0.46

2016-12-31

-0.81

2015-12-31

-0.25

2014-12-31

-0.56

2013-12-31

-0.74

2012-12-31

-0.48

2011-12-31

-0.19

2010-12-31

-0.56

2009-12-31

-0.67

2008-12-31

-0.61

2007-12-31

-0.32

2006-12-31

-0.24

2005-12-31

-0.26

2004-12-31

-0.26

2003-12-31

-0.01

2002-12-31

-0.01

2001-12-31

-0.03

Earnings Per Share (EPS): 3.35

HALO Earnings Per Share (EPS)

HALO Quarterly EPS Growth (YoY)

HALO P/E Ratio

HALO P/E Ratio Chart

HALO Average Earnings Per Share (EPS) Chart

HALO Current vs Average Earnings Per Share (EPS) Chart

HALO Earnings Per Share (EPS) Metrics

HALO Competitors' Earnings Per Share (EPS)

EPS Comparison

Earnings Per Share (EPS) Formula & Definition

Earnings Per Share (EPS) FAQ

HALO Earnings Per Share (EPS) History

Related Metrics

HALO PEG Ratio

HALO PEG Ratio Chart